Intra-Cellular Therapies Newsroom

Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100

Futu News01:32 · Ratings

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

TipRanksNov 28 09:47 · Ratings

Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM

Seeking AlphaNov 27 03:01

UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87

Futu NewsNov 20 02:31 · Ratings

Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79

BreakingsNov 19 23:39

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

GlobeNewswireNov 19 21:00

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 15:13

Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing

MT NewswiresNov 15 16:51

Intra-Cellular Therapies(ITCI.US) Officer Sells US$3.69 Million in Common Stock

$Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael sold 41,583 shares of common stock on Nov 12, 13, 2024 at an average price of $88.79 for a total value of $3.69 million.Source:

Futu NewsNov 15 07:08

Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 3.7 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Nov 12, $Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael intends to sell 41,583 shares of its common stock on Nov 12, with a total market value of approximately $3.

Futu NewsNov 13 05:34

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is Still On The Mark Following 26% Share Price Bounce

Simply Wall StNov 7 19:47

Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%

BenzingaNov 6 01:10

Intra-Cellular Meets Main Goal in Late Stage Trial for Its Schizophrenia Treatment

Seeking AlphaNov 5 21:53

Express News | Intra-Cellular Therapies Inc - Primary Endpoint Shows Longer Time to Relapse With Lumateperone

BreakingsNov 5 20:00

Express News | Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating Caplyta for the Prevention of Relapse in Patients With Schizophrenia

BreakingsNov 5 20:00

Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews

BenzingaNov 5 00:00

Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan

Dow JonesNov 4 22:34 · Ratings

J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $89

Futu NewsNov 4 21:31 · Ratings

Intra-Cellular Therapies Receives Buy Rating Amid Promising Sales Projections and Strategic Developments

TipRanksNov 4 20:35 · Ratings

Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results

Yahoo FinanceNov 2 21:33